← Leaderboards
Alexander Andrianov
Univ Of Maryland, College Park
$2,015,325
Attributed
$11,715,835
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,715,835 · 2
By mechanism
R01$11,715,835 · 2
Top collaborators
- Thomas R Fuerst10 shared
- Roy A Mariuzza10 shared
- Brian G. Pierce10 shared
- Steven Foung5 shared
- Gilad A Ofek5 shared
- Alexander Ploss5 shared
- Nevil John Singh5 shared
Most similar at Univ Of Maryland, College Park
Same institution · by research overlap
- Brian G. Pierce$5,043,672
- Thomas R Fuerst$2,156,141
- Gilad A Ofek$1,245,217
- Siba K Samal$1,024,194
- George A. Belov$4,227,596
Others in their field
Other Emerging Leaders on “Primary Carcinoma Of The Liver Cells”
- Amit Singal · Ut Southwestern Medical Center$15,537,004
- William H. Peranteau · Children'S Hosp Of Philadelphia$7,624,302
- Amaia Lujambio · Icahn School Of Medicine At Mount Sinai$5,368,450
- Valerian Nakaar · Carogen Corporation$4,718,929
- Cynthia A Moylan · Duke University$4,605,130
- Vera Hoffman · Reveal Pharma$4,535,285
Research focus
Primary Carcinoma Of The Liver CellsAntigensVirus EnvelopeImmunityHepatitis C VaccineLiver DiseasesNeutralizing AntibodyT-LymphocyteEpitopesB-LymphocytesAntibodiesImmunologicsGlycoproteinsImmunizeImmunogenicityFormulationGenotypeHydrogelsHepatitis C Virus Nucleocapsid ProteinClinical TrialsDesignImmune ResponseBindingCd81 Gene
Grant awards (10)
Rational design and efficacy testing of vaccines against HCV$1,357,012
R01 · FY2025 · AI
Rational design and efficacy testing of vaccines against HCV$1,410,043
R01 · FY2024 · AI
Rational design and efficacy testing of vaccines against HCV$179,958
R01 · FY2024 · AI
Rational design and efficacy testing of vaccines against HCV$1,379,680
R01 · FY2023 · AI
Rational design and efficacy testing of vaccines against HCV$1,410,544
R01 · FY2022 · AI
Structure-Based Vaccine Design for Hepatits C Virus$1,120,994
R01 · FY2021 · AI
Structure-Based Vaccine Design for Hepatits C Virus$1,128,779
R01 · FY2020 · AI
Structure-Based Vaccine Design for Hepatits C Virus$1,136,335
R01 · FY2019 · AI
Structure-Based Vaccine Design for Hepatits C Virus$1,142,860
R01 · FY2018 · AI
Structure-Based Vaccine Design for Hepatits C Virus$1,449,630
R01 · FY2017 · AI